Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

ARTICLES

How high school students are learning about labs

July 2025—Two years into its program to introduce high school students to laboratory careers, Mayo Clinic in Rochester, Minn., is seeing the hoped-for interest and demand. Discover Mayo Clinic Lab Explorers Program is the name, and the program is open to students in grades nine through 12. “Over the last two years, we’ve had roughly 100 students participate, and both times we opened registration it was full within three to five days,” says Liana Michelfelder, talent solutions specialist with the Mayo Clinic human resources workforce development team. In the program’s second year, which took place this year in April, she says, there was a 60-student waiting list. “So we are seeing strong results so far,” Michelfelder says.

Pathology student interest groups—what makes them work

July 2025—Seventy-eight percent of those responding to a survey said their institutions have a pathology student interest group, and they said the most effective ways to engage and retain students are hosting regular events; providing mentorship, leadership, and shadowing opportunities; and offering participation incentives. Using social media and online platforms was reported to be less effective. “A surprise in the findings was the student respondents’ desire to have more faculty engagement. So while students may want to start an interest group and are engaged, they have a hard time getting these off the ground if they don’t have faculty support,” says coauthor Kalisha Hill, MD, MBA. “We’re finding that when the faculty are engaged with these student interest groups, they are much more successful.”

AMP case report: Identifying the signal in the signal: incidental detection of B-cell lymphoproliferative disorder-related variants in the molecular profiling of a spindle cell sarcoma

July 2025—We report the case of a 75-year-old female who initially presented with a 10-cm left pretibial mass on MRI. A biopsy revealed a high-grade spindle cell sarcoma with myofibroblastic differentiation. PET CT showed intense uptake in osseous lesions at the scapula, vertebral bodies, iliac bones, sacrum, and femoral head. A sacrum biopsy confirmed metastatic spindle cell sarcoma. The patient underwent chemotherapy and radiotherapy. A follow-up CT scan several months later revealed new liver and lung metastases, prompting molecular analysis of the sacrum specimen.

‘Stick to the basics’: service, quality, and cost

July 2025—What’s new from Roche, Hologic, and Siemens Healthineers, and how they aim to lighten for labs the burden of the workforce shortage. CAP TODAY publisher Bob McGonnagle spoke about these and other things with three company representatives in an online roundtable, and Stan Schofield, Compass Group managing principal, told them what three questions companies must answer to get a laboratory’s business. Their June 2 conversation follows.

Spectrum of anti-PF4 disorders widens

June 2025—For a relatively sleepy field of study, heparin-induced thrombocytopenia has produced more than its share of thrills in the past few years. HIT (sometimes called HITT, with the extra “T” denoting thrombosis) gave way to urgent discussions about vaccine-induced immune thrombotic thrombocytopenia, or VITT, at one particularly panicky point in the COVID-19 pandemic. Take another spin of the wheel: “VITT-like” is now primarily used to refer to cases in which patients have received neither heparin nor a vaccine. Even more recently, researchers have identified a new syndrome, referred to as monoclonal gammopathy of thrombotic significance (MGTS). Publications have put this disorder into three groups. “I think this is going to be the biggest thing in the thrombophilia field in a long time,” predicts Anand Padmanabhan, MD, PhD, professor, Mayo Clinic. Unlike HIT and VITT, MGTS is a chronic condition. “It may end up being part of a thrombophilia profile in the coming years.”

Breast HER2 FISH groups 2 and 4: study of excision specimens

June 2025—The authors of a recently published study suggest repeating HER2 testing on the excision specimen for the small number of breast cancer biopsies with group two and group four FISH results. The aim of their study was to determine if FISH group two and group four cases change HER2 status after repeated testing on additional specimens.

Tumor marker testing in body fluids calls for caution

June 2025—With few FDA-cleared or -approved methods for tumor marker testing in body fluids, it is the laboratory that’s responsible for the tests. “A specimen arrives at your door, and you have to figure out what, if anything, you’re going to do,” said Jonathan Genzen, MD, PhD, MBA.

A pathologist’s reflections after visiting a zipper factory

June 2025—Some years back, I flew south from New England, where I work as an academic cytopathologist, to North Carolina. My destination was an academic medical center where I was to give a talk on fine-needle aspiration biopsies. On my drive from the airport, I detoured to a small city that housed a company that manufactures zippers. There, on the factory floor, I watched newly made zippers exiting from rows of heavy steel machines. I asked myself: How is that like what we do as pathologists?

No MI? What Atellica hs-cTnI says about future risk

June 2025—Patients who present to the ED with an elevated cardiac troponin above the 99th percentile and suspected acute coronary syndrome but in whom myocardial infarction is not diagnosed are at risk for future cardiac events. But how much risk? Last fall, the Food and Drug Administration cleared Siemens Healthineers’ Atellica IM High-Sensitivity Troponin I assay for prognostic risk stratification, an expanded intended use claim. Now, with this newly cleared use, “novel information is created from traditional indications,” said Christopher deFilippi, MD, who was recently director of the Biocore research laboratory and vice chair of academic affairs, Inova Schar Heart and Vascular in Fairfax, Va., and is now, since June 1, at the University of Maryland.

MARKETPLACE

TRENDING